Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-55111
Clin Pharmacol Ther 2026 Jul 05;1201:109-113. doi: 10.1002/cpt.70256.
Show Gene links Show Anatomy links

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis.

Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Maconi G, Gravina AG, Pellegrino R, Bodini G, Savarino EV, Papa A, Italian Network for Inflammatory Bowel Diseases (IN‐IBD).


???displayArticle.abstract???
We evaluated whether concomitant 5-aminosalicylic acid (5-ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included. Time to clinical remission was analyzed using interval-censored Cox models. Among the 633 patients treated with JAKi, 476 patients received 5-ASA, and 151 did not. Cumulative probability of remission at week 48 was similar with and without 5-ASA, at 81.3% and 77.0%, respectively. The adjusted hazard ratio for 5-ASA vs. no 5-ASA was 1.12 (95% CI 0.91-1.37, P = 0.519). We therefore found that concomitant 5-ASA did not significantly affect the time to clinical remission in UC patients treated with JAKi.

???displayArticle.pubmedLink??? 41786642
???displayArticle.pmcLink??? PMC13264456
???displayArticle.link??? Clin Pharmacol Ther




???attribute.lit??? ???displayArticles.show???